Neprilysin: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
rm {{en}}: if someone wants to revert, please use {{en icon}} instead; formatting: 5x whitespace, 4x heading-style, heading (using Advisor.js)
substituted more cite pmid templates
Line 32: Line 32:
* Burkitt Lymphoma are CD10<sup>+</sup>.
* Burkitt Lymphoma are CD10<sup>+</sup>.
* CD10<sup>+</sup> diffuse large B cell lymphoma (CD10<sup>+</sup> DLBLC)<ref name="pmid22431545">{{cite journal | author = McGowan P, Nelles N, Wimmer J, Williams D, Wen J, Li M, Ewton A, Curry C, Zu Y, Sheehan A, Chang CC | title = Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system | journal = Am. J. Clin. Pathol. | volume = 137 | issue = 4 | pages = 665–70 | year = 2012 | pmid = 22431545 | doi = 10.1309/AJCP3FEPX5BEEKGX }}</ref>
* CD10<sup>+</sup> diffuse large B cell lymphoma (CD10<sup>+</sup> DLBLC)<ref name="pmid22431545">{{cite journal | author = McGowan P, Nelles N, Wimmer J, Williams D, Wen J, Li M, Ewton A, Curry C, Zu Y, Sheehan A, Chang CC | title = Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system | journal = Am. J. Clin. Pathol. | volume = 137 | issue = 4 | pages = 665–70 | year = 2012 | pmid = 22431545 | doi = 10.1309/AJCP3FEPX5BEEKGX }}</ref>
** Marker for germinal center phenotype (CD10, HGAL, BCL6, CD38) are considered a favorable prognostic factor,<ref name="pmid15920553">{{cite journal | author = Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, Sundström C, Rehn-Eriksson S, Backlin C, Hagberg H, Rosenquist R, Enblad G | title = Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis | journal = Mod. Pathol. | volume = 18 | issue = 8 | pages = 1113–20 | year = 2005 | pmid = 15920553 | doi = 10.1038/modpathol.3800396 }}</ref><ref>{{Cite pmid|20309427}}</ref> but CD10<sup>+</sup>, BCL2+ tumors could have poorer survival.<ref name="pmid11488064">{{cite journal | author = Xu Y, McKenna RW, Molberg KH, Kroft SH | title = Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2 | journal = Am. J. Clin. Pathol. | volume = 116 | issue = 2 | pages = 183–90 | year = 2001 | pmid = 11488064 | doi = 10.1309/J7RN-UXAY-55GX-BUNK }}</ref> For some authors, CD10 expression in DLBCL does not influence survival.<ref>{{Cite pmid|15517363}}</ref>
** Marker for germinal center phenotype (CD10, HGAL, BCL6, CD38) are considered a favorable prognostic factor,<ref name="pmid15920553">{{cite journal | author = Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, Sundström C, Rehn-Eriksson S, Backlin C, Hagberg H, Rosenquist R, Enblad G | title = Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis | journal = Mod. Pathol. | volume = 18 | issue = 8 | pages = 1113–20 | year = 2005 | pmid = 15920553 | doi = 10.1038/modpathol.3800396 }}</ref><ref name="pmid20309427">{{cite journal | author = Höller S, Horn H, Lohr A, Mäder U, Katzenberger T, Kalla J, Bernd HW, Went P, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G | title = A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score | journal = J Hematop | volume = 2 | issue = 4 | pages = 187–94 | year = 2009 | pmid = 20309427 | pmc = 2798934 | doi = 10.1007/s12308-009-0044-x }}</ref> but CD10<sup>+</sup>, [[BCL2]]<sup>+ </sup>tumors could have poorer survival.<ref name="pmid11488064">{{cite journal | author = Xu Y, McKenna RW, Molberg KH, Kroft SH | title = Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2 | journal = Am. J. Clin. Pathol. | volume = 116 | issue = 2 | pages = 183–90 | year = 2001 | pmid = 11488064 | doi = 10.1309/J7RN-UXAY-55GX-BUNK }}</ref> For some authors, CD10 expression in DLBCL does not influence survival.<ref name="pmid15517363">{{cite journal | author = Fabiani B, Delmer A, Lepage E, Guettier C, Petrella T, Brière J, Penny AM, Copin MC, Diebold J, Reyes F, Gaulard P, Molina TJ | title = CD10 expression in diffuse large B-cell lymphomas does not influence survival | journal = Virchows Arch. | volume = 445 | issue = 6 | pages = 545–51 | year = 2004 | pmid = 15517363 | doi = 10.1007/s00428-004-1129-7 }}</ref>
* [[Angioimmunoblastic T cell lymphoma]] (AITL) are CD10<sup>+</sup><ref name="pmid21499231">{{cite journal | author = Baseggio L, Traverse-Glehen A, Berger F, Ffrench M, Jallades L, Morel D, Goedert G, Magaud JP, Salles G, Felman P | title = CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma | journal = Mod. Pathol. | volume = 24 | issue = 7 | pages = 993–1003 | year = 2011 | pmid = 21499231 | doi = 10.1038/modpathol.2011.53 }}</ref><ref name="pmid16084948">{{cite journal | author = Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A | title = CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry | journal = Hum. Pathol. | volume = 36 | issue = 7 | pages = 784–91 | year = 2005 | pmid = 16084948 | doi = 10.1016/j.humpath.2005.05.008 }}</ref> and distinguishes AITL from other T cell lymphomas (CD10<sup>–</sup>)<ref name="pmid14707864">{{cite journal | author = Attygalle AD, Diss TC, Munson P, Isaacson PG, Du MQ, Dogan A | title = CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma | journal = Am. J. Surg. Pathol. | volume = 28 | issue = 1 | pages = 54–61 | year = 2004 | pmid = 14707864 | doi = }}</ref>
* [[Angioimmunoblastic T cell lymphoma]] (AITL) are CD10<sup>+</sup><ref name="pmid21499231">{{cite journal | author = Baseggio L, Traverse-Glehen A, Berger F, Ffrench M, Jallades L, Morel D, Goedert G, Magaud JP, Salles G, Felman P | title = CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma | journal = Mod. Pathol. | volume = 24 | issue = 7 | pages = 993–1003 | year = 2011 | pmid = 21499231 | doi = 10.1038/modpathol.2011.53 }}</ref><ref name="pmid16084948">{{cite journal | author = Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A | title = CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry | journal = Hum. Pathol. | volume = 36 | issue = 7 | pages = 784–91 | year = 2005 | pmid = 16084948 | doi = 10.1016/j.humpath.2005.05.008 }}</ref> and distinguishes AITL from other T cell lymphomas (CD10<sup>–</sup>)<ref name="pmid14707864">{{cite journal | author = Attygalle AD, Diss TC, Munson P, Isaacson PG, Du MQ, Dogan A | title = CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma | journal = Am. J. Surg. Pathol. | volume = 28 | issue = 1 | pages = 54–61 | year = 2004 | pmid = 14707864 | doi = }}</ref>
** Some benign T cells can be CD10<sup>+</sup><ref name="pmid13679451">{{cite journal | author = Cook JR, Craig FE, Swerdlow SH | title = Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas | journal = Mod. Pathol. | volume = 16 | issue = 9 | pages = 879–85 | year = 2003 | pmid = 13679451 | doi = 10.1097/01.MP.0000084630.64243.D1 }}</ref>
** Some benign T cells can be CD10<sup>+</sup><ref name="pmid13679451">{{cite journal | author = Cook JR, Craig FE, Swerdlow SH | title = Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas | journal = Mod. Pathol. | volume = 16 | issue = 9 | pages = 879–85 | year = 2003 | pmid = 13679451 | doi = 10.1097/01.MP.0000084630.64243.D1 }}</ref>
Line 48: Line 48:
** CD10 differentiates CD10<sup>+</sup> [[atypical fibroxanthoma]] from CD10<sup>–</sup> spindle cell [[melanoma]] and sarcomatoid [[squamous cell carcinoma]].
** CD10 differentiates CD10<sup>+</sup> [[atypical fibroxanthoma]] from CD10<sup>–</sup> spindle cell [[melanoma]] and sarcomatoid [[squamous cell carcinoma]].


* [[Urothelial tumor]]s express CD10 (42-67%).<ref>{{Cite pmid|16191505}}</ref>
* [[Urothelial tumor]]s express CD10 (42-67%).<ref name="pmid16191505">{{cite journal | author = Murali R, Delprado W | title = CD10 immunohistochemical staining in urothelial neoplasms | journal = Am. J. Clin. Pathol. | volume = 124 | issue = 3 | pages = 371–9 | year = 2005 | pmid = 16191505 | doi = 10.1309/04BH-F6A8-0BQM-H7HT }}</ref>
** CD10 expression is strongly correlated with high tumor grade and stage in urothelial carcinoma of the bladder. CD10 may be associated with tumor progression in bladder cancer pathogenesis. <ref>{{Cite pmid|19917108}}</ref>
** CD10 expression is strongly correlated with high tumor grade and stage in urothelial carcinoma of the bladder. CD10 may be associated with tumor progression in bladder cancer pathogenesis.<ref name="pmid19917108">{{cite journal | author = Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO | title = CD10 expression in urothelial carcinoma of the bladder | journal = Diagn Pathol | volume = 4 | issue = | pages = 38 | year = 2009 | pmid = 19917108 | pmc = 2780995 | doi = 10.1186/1746-1596-4-38 }}</ref>


=== In other tumors ===
=== In other tumors ===

Revision as of 07:18, 22 February 2014

Template:PBB

Neprilysin, also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 (CD10), and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin.[1] it also degrades the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been implicated as a cause of Alzheimer's disease. Synthesized as a membrane-bound protein, the neprilysin ectodomain is released into the extracellular domain after it has been transported from the Golgi apparatus to the cell surface.

Neprilysin is expressed in a wide variety of tissues and is particularly abundant in kidney. It is also a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). This protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL.[1]

Hematopoetic Progenitors expressing CD10 are considered "Common Lymphoid Progenitors," which means they can differentiate into T, B or Natural Killer cells.[2] CD10 is of use in hematological diagnosis since it is expressed by early B, pro-B and pre-B lymphocytes, and by lymph node germinal centers.[3] Hematologic diseases in which it is positive include ALL, angioimmunoblastic T cell lymphoma, Burkitt lymphoma, CML in blast crisis (90%), diffuse large B-cell lymphoma (variable), follicular center cells (70%), hairy cell leukemia (10%), and myeloma (some). It tends to be negative in AML, CLL, mantle cell lymphoma, and marginal zone lymphoma. CD10 is found on non-T ALL cells, which derive from pre-B lymphocytes, and in germinal center-related non-Hodgkin lymphoma such as Burkitt lymphoma and follicular lymphoma, but not on leukemia cells or lymphomas, which originate in more mature B cells.[4]

Amyloid beta regulation

Neprilysin-deficient knockout mice show both Alzheimer's-like behavioral impairment and amyloid-beta deposition in the brain,[5] providing strong evidence for the protein's association with the Alzheimer's disease process. Because neprilysin is thought to be the rate-limiting step in amyloid beta degradation,[6] it has been considered a potential therapeutic target; compounds such as the peptide hormone somatostatin have been identified that increase the enzyme's activity level.[7] One hypothesis for the strong dependence of Alzheimer's incidence on age focuses on the declining production of somatostatin in the brains of elderly people, which thus depresses the activity of neprilysin and promotes aggregation of unprocessed amyloid beta.[8] Declining neprilysin activity with increasing age may also be explained by oxidative damage, known to be a causative factor in Alzheimer's disease; higher levels of inappropriately oxidized neprilysin have been found in Alzheimer's patients compared to cognitively normal elderly people.[9]

Signaling peptides

Neprilysin immunohistochemical staining of normal kidney.

Neprilysin is also associated with other biochemical processes, and is particularly highly expressed in kidney and lung tissues. Inhibitors have been designed with the aim of developing analgesic and antihypertensive agents that act by preventing neprilysin's activity against signaling peptides such as enkephalins, substance P, endothelin, and atrial natriuretic factor.[10][11]

Associations have been observed between neprilysin expression and various types of cancer; however, the relationship between neprilysin expression and carcinogenesis remains obscure. In cancer biomarker studies, the neprilysin gene is often referred to as CD10 or CALLA. In some types of cancer, such as metastatic carcinoma and some advanced melanomas, neprilysin is overexpressed;[12] in other types, most notably lung cancers, neprilysin is downregulated, and thus unable to modulate the pro-growth autocrine signaling of cancer cells via secreted peptides such as mammalian homologs related to bombesin.[13] Some plant extracts (methanol extracts of Ceropegia rupicola, Kniphofia sumarae, Plectranthus cf barbatus, and an aqueous extract of Pavetta longiflora) were found able to inhibit the enzymatic activity of neutral endopeptidase.[14]

Inhibitors

Immunochemistry

CD10 is used in clinical pathology for diagnostic purpose.

In lymphomas and leukemias

  • Acute lymphoblastic leukemia (ALL) cells are CD10+.
  • Follicular lymphoma (follicle centre cell lymphoma) are CD10+.
  • Burkitt Lymphoma are CD10+.
  • CD10+ diffuse large B cell lymphoma (CD10+ DLBLC)[15]
    • Marker for germinal center phenotype (CD10, HGAL, BCL6, CD38) are considered a favorable prognostic factor,[16][17] but CD10+, BCL2+ tumors could have poorer survival.[18] For some authors, CD10 expression in DLBCL does not influence survival.[19]
  • Angioimmunoblastic T cell lymphoma (AITL) are CD10+[20][21] and distinguishes AITL from other T cell lymphomas (CD10–)[22]
    • Some benign T cells can be CD10+[23]

In epithelial tumors

  • Clear cell renal cell carcinoma (Clear cell RCC)
    • CD10+ distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers. Chromophobe carcinoma and oncocytoma are CD10-.[24]
  • Urothelial tumors express CD10 (42-67%).[28]
    • CD10 expression is strongly correlated with high tumor grade and stage in urothelial carcinoma of the bladder. CD10 may be associated with tumor progression in bladder cancer pathogenesis.[29]

In other tumors

See also

References

  1. ^ a b "Entrez Gene: Membrane metallo-endopeptidase".
  2. ^ Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. http://www.ncbi.nlm.nih.gov/pubmed/7584137
  3. ^ Singh C (2011-02-25). "CD10". CD Markers. PathologyOutlines.com, Inc.
  4. ^ Papandreou CN, Nanus DM (January 2010). "Is methylation the key to CD10 loss?". J. Pediatr. Hematol. Oncol. 32 (1): 2–3. doi:10.1097/MPH.0b013e3181c74aca. PMID 20051779.
  5. ^ Madani R, Poirier R, Wolfer DP, Welzl H, Groscurth P, Lipp HP, Lu B, El Mouedden M, Mercken M, Nitsch RM, Mohajeri MH (December 2006). "Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo". J. Neurosci. Res. 84 (8): 1871–8. doi:10.1002/jnr.21074. PMID 16998901.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (February 2000). "Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition". Nat. Med. 6 (2): 143–50. doi:10.1038/72237. PMID 10655101.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Iwata N, Higuchi M, Saido TC (November 2005). "Metabolism of amyloid-beta peptide and Alzheimer's disease". Pharmacol. Ther. 108 (2): 129–48. doi:10.1016/j.pharmthera.2005.03.010. PMID 16112736.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Hama E, Saido TC (2005). "Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide". Med. Hypotheses. 65 (3): 498–500. doi:10.1016/j.mehy.2005.02.045. PMID 15921860.
  9. ^ Wang DS, Iwata N, Hama E, Saido TC, Dickson DW (October 2003). "Oxidized neprilysin in aging and Alzheimer's disease brains". Biochem. Biophys. Res. Commun. 310 (1): 236–41. doi:10.1016/j.bbrc.2003.09.003. PMID 14511676.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Sahli S, Stump B, Welti T, Schweizer WB, Diederich R, Blum-Kaelin D, Aebi JD, Böhm H-J (April 2005). "A New Class of Inhibitors for the Metalloprotease Neprilysin Based on a Central Imidazole Scaffold". Helvetica Chimica Acta. 88 (4): 707–730. doi:10.1002/hlca.200590050.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE (February 2004). "Structural analysis of neprilysin with various specific and potent inhibitors". Acta Crystallogr. D Biol. Crystallogr. 60 (Pt 2): 392–6. doi:10.1107/S0907444903027410. PMID 14747736.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, O'Neill D, Yu YL, Spira J, Christos PJ, Zhou XK, Mazumdar M, Nanus DM, Liebes L, Bhardwaj N, Polsky D, Osman I (2007). "Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma". J Transl Med. 5: 2. doi:10.1186/1479-5876-5-2. PMC 1770905. PMID 17207277.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  13. ^ Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE (February 1996). "Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux". Cancer Res. 56 (4): 831–9. PMID 8631021.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ^ Alasbahi R, Melzig MF (January 2008). "Screening of some Yemeni medicinal plants for inhibitory activity against peptidases". Pharmazie. 63 (1): 86–8. PMID 18271311.
  15. ^ McGowan P, Nelles N, Wimmer J, Williams D, Wen J, Li M, Ewton A, Curry C, Zu Y, Sheehan A, Chang CC (2012). "Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system". Am. J. Clin. Pathol. 137 (4): 665–70. doi:10.1309/AJCP3FEPX5BEEKGX. PMID 22431545.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ^ Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, Sundström C, Rehn-Eriksson S, Backlin C, Hagberg H, Rosenquist R, Enblad G (2005). "Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis". Mod. Pathol. 18 (8): 1113–20. doi:10.1038/modpathol.3800396. PMID 15920553.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ^ Höller S, Horn H, Lohr A, Mäder U, Katzenberger T, Kalla J, Bernd HW, Went P, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G (2009). "A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score". J Hematop. 2 (4): 187–94. doi:10.1007/s12308-009-0044-x. PMC 2798934. PMID 20309427.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  18. ^ Xu Y, McKenna RW, Molberg KH, Kroft SH (2001). "Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2". Am. J. Clin. Pathol. 116 (2): 183–90. doi:10.1309/J7RN-UXAY-55GX-BUNK. PMID 11488064.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  19. ^ Fabiani B, Delmer A, Lepage E, Guettier C, Petrella T, Brière J, Penny AM, Copin MC, Diebold J, Reyes F, Gaulard P, Molina TJ (2004). "CD10 expression in diffuse large B-cell lymphomas does not influence survival". Virchows Arch. 445 (6): 545–51. doi:10.1007/s00428-004-1129-7. PMID 15517363.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  20. ^ Baseggio L, Traverse-Glehen A, Berger F, Ffrench M, Jallades L, Morel D, Goedert G, Magaud JP, Salles G, Felman P (2011). "CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma". Mod. Pathol. 24 (7): 993–1003. doi:10.1038/modpathol.2011.53. PMID 21499231.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  21. ^ Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A (2005). "CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry". Hum. Pathol. 36 (7): 784–91. doi:10.1016/j.humpath.2005.05.008. PMID 16084948.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. ^ Attygalle AD, Diss TC, Munson P, Isaacson PG, Du MQ, Dogan A (2004). "CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma". Am. J. Surg. Pathol. 28 (1): 54–61. PMID 14707864.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. ^ Cook JR, Craig FE, Swerdlow SH (2003). "Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas". Mod. Pathol. 16 (9): 879–85. doi:10.1097/01.MP.0000084630.64243.D1. PMID 13679451.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  24. ^ Yasir S, Herrera L, Gomez-Fernandez C, Reis IM, Umar S, Leveillee R, Kava B, Jorda M (2012). "CD10+ and CK7/RON- immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers". Appl. Immunohistochem. Mol. Morphol. 20 (5): 454–61. doi:10.1097/PAI.0b013e31823fecd3. PMID 22417859.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  25. ^ a b Notohara K, Hamazaki S, Tsukayama C, Nakamoto S, Kawabata K, Mizobuchi K, Sakamoto K, Okada S (2000). "Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10". Am. J. Surg. Pathol. 24 (10): 1361–71. PMID 11023097.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  26. ^ Córdoba A, Guerrero D, Larrinaga B, Iglesias ME, Arrechea MA, Yanguas JI (2009). "Bcl-2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation". Int. J. Dermatol. 48 (7): 713–7. doi:10.1111/j.1365-4632.2009.04076.x. PMID 19570076.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  27. ^ Sari Aslani F, Akbarzadeh-Jahromi M, Jowkar F (2013). "Value of CD10 Expression in Differentiating Cutaneous Basal from Squamous Cell Carcinomas and Basal Cell Carcinoma from Trichoepithelioma". Iran J Med Sci. 38 (2): 100–6. PMC 3700055. PMID 23825889.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  28. ^ Murali R, Delprado W (2005). "CD10 immunohistochemical staining in urothelial neoplasms". Am. J. Clin. Pathol. 124 (3): 371–9. doi:10.1309/04BH-F6A8-0BQM-H7HT. PMID 16191505.
  29. ^ Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO (2009). "CD10 expression in urothelial carcinoma of the bladder". Diagn Pathol. 4: 38. doi:10.1186/1746-1596-4-38. PMC 2780995. PMID 19917108.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  30. ^ a b Mikami Y, Hata S, Kiyokawa T, Manabe T (2002). "Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study". Mod. Pathol. 15 (9): 923–30. doi:10.1097/01.MP.0000026058.33869.DB. PMID 12218209.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  31. ^ McCluggage WG, Sumathi VP, Maxwell P (2001). "CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms". Histopathology. 39 (3): 273–8. PMID 11532038.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005). "Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer". J. Clin. Oncol. 23 (16): 3706–12. doi:10.1200/JCO.2005.00.232. PMID 15867200.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  33. ^ Weinreb I, Cunningham KS, Perez-Ordoñez B, Hwang DM (2009). "CD10 is expressed in most epithelioid hemangioendotheliomas: a potential diagnostic pitfall". Arch. Pathol. Lab. Med. 133 (12): 1965–8. doi:10.1043/1543-2165-133.12.1965. PMID 19961253.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  34. ^ Jung SM, Kuo TT (2005). "Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma". Mod. Pathol. 18 (6): 788–94. doi:10.1038/modpathol.3800351. PMID 15578072.
  35. ^ Yin WH, Li J, Chan JK (2012). "Sporadic haemangioblastoma of the kidney with rhabdoid features and focal CD10 expression: report of a case and literature review". Diagn Pathol. 7: 39. doi:10.1186/1746-1596-7-39. PMC 3364142. PMID 22497861.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Neprilysin&oldid=596603117"